Calgary, Alberta — August 19, 2025 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) will host a webinar on August 21, 2025, to discuss its integration of AI across patient engagement, clinical research, and corporate operations. Croom Lawrence, Chief Commercialization Officer, who completed executive education in Artificial Intelligence and Healthcare at MIT, will present the phased approach.
According to CEO Thomas Smeenk, the webinar will showcase the transformation of Hemostemix into the world’s first AI-driven autologous stem cell therapy company treating pain associated with no-option patients under Florida’s SB1768. Croom Lawrence emphasized that AI-based workflows improve patient experience, recruitment, trials, analytics, patient outcomes, and patient care.
Patient care innovations include HIPAA-Compliant Precision Medicine Diagnostics, Acurist.AI for Early Cognitive Decline, AI-Powered Patient Engagement, and Patient Decision Support Tools. Clinical and scientific advancements feature accelerated research with AI, predictive analytics for VesCell™ outcomes, and AI for trial matching. Operational efficiency improvements cover automated administrative workflows, AI-optimized resource allocation, a unified data ecosystem, and proactive compliance & security.
The webinar is scheduled for August 21, 2025, at 12:00 PM EST. Format: Webinar – https://www.vescell.health/events
Hemostemix, founded in 2003, has developed, patented, and is scaling autologous blood-based stem cell therapy, VesCell™ (ACP-01). The company has completed seven clinical studies and published results in 11 peer-reviewed publications. ACP-01 is considered safe and clinically relevant for treating various conditions. Hemostemix completed its Phase II clinical trial for chronic limb-threatening ischemia, reporting positive results.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
